Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

The beatdown in MRNA stock seems overdone as it presents encouraging Covid-19 vaccine results and seeks a crucial regulatory approval. The post Target Deep Value and Give Moderna a Shot appeared first on InvestorPlace.

Target Deep Value and Give Moderna a Shot

Moderna Inc's (NASDAQ: MRNA) chief medical officer said that its COVID-19 vaccine for children under six years old would be ready for review by the FDA panel when it meets in June. "I think the FDA now has all of the core fundamental data they need to be able to begin an.

Moderna Bullish On COVID-19 Vaccine For Younger Kids To Be Ready Next Month: Reuters

Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the first-quarter earnings call that can help it to reduce its dependence on Spikevax.

Is a Beat Likely for Moderna (MRNA) This Earnings Season?

Moderna, Inc (NASDAQ: MRNA) was trading over 8% higher at one point on Monday morning, bouncing up within a descending channel pattern on the daily chart. In the pattern, a stock makes a series of lower lows and lower highs between two parallel trendlines.

Here's What To Watch On Moderna As The Stock Flies Higher

Moderna Inc  (NASDAQ:MRNA) is up 5.1% at $141.25 this morning, after the U.S. Food and Drug Administration (FDA) announced an advisory panel of experts will meet in June to review the use of its Covid-19 vaccine in children under six years old.

Moderna Eyes FDA Review of Covid-19 Vaccine for Young Children

With the help of its new subsidiaries and distribution partnerships, Moderna can sell more COVID-19 vaccines to the world in 2022 than in 2021. Moderna COVID-19 vaccine's third dose market share has increased significantly in Germany, France, Italy, Spain, and South Korea.

Moderna Stock: Undervalued Ahead Of Q1 Earnings

It could offer us clues about revenue over the next couple of years.

You Won't Want to Miss This 1 Thing in Moderna's Earnings Report

Airbnb

Advanced Micro Devices

WisdomTree U.S. Earnings 500 Fund

Marriott

Pfizer

Starbucks

Data from FactSet shows that with only 20% of S&P 500 companies having reported first quarter results, 79% have announced better than expected earnings per share (EPS), while 69% have reported better revenue than Wall Street had forecast. The post 7 Stocks Reporting Earnings the Week of May 2 appeared first on InvestorPlace.

7 Stocks Reporting Earnings the Week of May 2

Vertex Pharmaceuticals

These two companies have moved in opposite directions on the stock market so far this year, but now seem set to move up and to the right.

2 Biotech Stocks to Buy and Hold for 10 Years

Novavax

The FDA has set up June meeting dates to review COVID-19 vaccine submissions, noting that the dates are tentative as none of the submissions are complete.   The agency reserved June 8, 21, and 22 for virtual meetings of the Vaccines and Related Biological Products Advisory.

FDA Sets Review Dates For Pfizer, Moderna COVID-19 Shot For Kids, Plus Novavax EUA

Shares of Moderna Inc. MRNA, -1.06% said Friday that it asked the European Medicines Agency to authorize its COVID-19 vaccine for use in children between the ages of 6 months and 6 years old. The company also filed for authorization in this age group in the U.S. this week.

Moderna files for authorization of its COVID-19 vaccine in young children in Europe

The filing follows the European Medicines Agency's Committee for Medicinal Products for Human Use recent decision to adopt a positive opinion recommending marketing authorization for Moderna's COVID-19 vaccine to include children six years of age and older. CAMBRIDGE, MA / ACCESSWIRE / April 29, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has submitted for a variation to the conditional marketing authorization (CMA) with the European Medicines Agency (EMA) for the evaluation of a 25 µg two-dose series of Spikevax, the Company's vaccine against COVID-19, in children six months to under six years of age.

Moderna Files to Expand Conditional Marketing Authorization for Its COVID-19 Vaccine to Include Children Six Months to Under Six Years in The European Union

The meetings are a sign that the vaccines are moving closer to a possible authorization.

FDA panel to discuss Novavax Covid vaccine for adults, Pfizer and Moderna shots for kids in June

Making drugs is getting harder, and it might not get easier anytime soon.

2 Charts That Every Biotech Investor Must See

Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually The ten-year strategic partnership is expected to provide Canadians with rapid response capabilities to ensure future pandemic readiness CAMBRIDGE, MA / ACCESSWIRE / April 29, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its plan to build a state-of-the-art mRNA vaccine manufacturing facility in Quebec that will support a long-term strategic partnership with the Government of Canada to enhance pandemic preparedness. This milestone follows the signing of a Memorandum of Understanding between Moderna and the Government of Canada in August 2021.

Moderna Finalizes Plan for Long-Term Strategic Partnership with The Government of Canada

Biogen

Novo Nordisk

Regeneron Pharmaceuticals

Let us take a look at some pharma/biotech stocks, REGN, BIIB, NVO, VRTX and MRNA that are poised to beat on first-quarter earnings.

5 Big Pharma, Biotech Stocks Set to Beat Q1 Earnings Estimates

Only 21% of parents of children under five said in February that they'd vaccinate their child “right away.”

Moderna Asks FDA To Authorize Covid Vaccines For Young Kids — But Most Parents Are In No Rush, Polls Suggest

If authorized, it will be the first COVID vaccine available for very young children.

Moderna Asks FDA to Authorize COVID Vaccine for Kids Under 6

Moderna (MRNA) stock could get a boost after the company revealed an application with the FDA for its Covid-19 vaccine in kids. The post MRNA Stock Alert: 11 Things to Know as Moderna Seeks FDA Vaccine Approval for Kids appeared first on InvestorPlace.

MRNA Stock Alert: 11 Things to Know as Moderna Seeks FDA Vaccine Approval for Kids

Moderna said it had applied to the FDA for emergency-use authorization for its COVID-19 vaccine for kids between 6 months and 6 years.

Moderna asks FDA to OK its coronavirus shot for kids under 6

Moderna is seeking emergency use authorization for its vaccine in children ages 6 months through five years which, if granted, will mark the first time Covid shots are available to young children.

Moderna Asks FDA To Authorize Covid Vaccine In Children As Young As 6 Months

Shares of Moderna Inc. MRNA, -2.30% gained 2.1% in premarket trading on Thursday after the company said it filed for authorization of its COVID-19 vaccine in children between the ages of 6 months and 6 years old. The submission is set to be completed next week, and is broken out into two categories: 6 month olds to 2 year olds, for which the vaccine has a 51% efficacy rate, and children between the ages of 2 and 6 years old, for which the efficacy rate was 37%.

Moderna asks the FDA to authorize its COVID-19 vaccine in young children

Submission to Regulators Globally Is Based on Phase 2/3 Studies of mRNA-1273 in Young Children CAMBRIDGE, MA / ACCESSWIRE / April 28, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has submitted a request for emergency use authorization (EUA) for its COVID-19 vaccine (mRNA-1273) in children 6 months to under 2 years and 2 years to under 6 years of age to the U.S. Food and Drug Administration and that similar requests are underway with international regulatory authorities. The requests are based on a 25 μg two-dose primary series of mRNA-1273.

Moderna Files for Authorization of Its COVID-19 Vaccine in Young Children Six Months to Under Six Years of Age

The FDA has promised to move quickly to authorize shots for infants, toddlers and preschoolers once the vaccine makers submit complete applications.

Moderna asks FDA to authorize Covid vaccine for kids under 6 years old

The head of the World Health Organization will present a shareholder resolution at the annual meeting of Moderna Inc on Thursday, a rare step into investor advocacy by the United Nations agency.

News for Moderna Stock (MRNA)